SequelSEC

TransMedics Group, Inc. TMDX

Electromedical & Electrotherapeutic Apparatus · CIK 0001756262 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$189.95M
Fiscal year ended 2026-06-30
Operating income
$23.74M
Fiscal year ended 2026-06-30
Free cash flow
$10.22M
Fiscal year ended 2026-06-30

TransMedics Group, Inc. (TMDX) reported revenue of $189.95M and net income of $14.68M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from TransMedics Group, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Electromedical & Electrotherapeutic Apparatus.

Income

TransMedics Group, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$189.95M$173.93M$160.76M$143.82M$157.37M$143.54M$121.62M$108.76M$114.30M$96.85M
Cost of revenue$76.75M$72.77M$67.35M$59.25M$60.78M$55.31M$49.61M$47.92M$45.04M$36.89M
Gross profit$113.20M$101.16M$93.41M$84.58M$96.59M$88.23M$72.01M$60.84M$69.26M$59.96M
Operating income$23.74M$13.30M$21.27M$23.30M$36.57M$27.44M$8.64M$3.92M$12.51M$12.42M
Net income$14.68M$7.32M$105.38M$24.32M$34.91M$25.68M$6.86M$4.22M$12.19M$12.20M
Research & development$31.63M$24.88M$20.70M$15.26M$15.93M$17.16M$16.46M$14.27M$13.86M$11.38M
Weighted-average diluted sharesshares 40.71Mshares 36.19MUnavailableshares 40.75Mshares 40.56Mshares 39.91MUnavailableshares 35.68Mshares 35.29Mshares 34.68M
Pretax income$19.40M$8.48M$21.63M$23.03M$36.18M$26.68M$6.99M$4.24M$12.15M$12.39M
Income tax expense$4.72M$1.17M-$83.75M-$1.29M$1.28M$994.00K$132.00K$29.00K-$41.00K$196.00K
Diluted EPS$0.41$0.20Unavailable$0.66$0.92$0.70Unavailable$0.12$0.35$0.35
Selling, general & administrative$57.83M$62.98M$51.44M$46.02M$44.09M$43.62M$46.90M$42.66M$42.90M$36.16M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

TransMedics Group, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalentsUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$330.09M$362.75M$350.22M
Total assets$1.46B$1.43B$1.07B$946.03M$890.52M$837.53M$804.08M$785.57M$758.58M$723.83M
Current assets$651.12M$619.28M$637.78M$613.00M$558.13M$505.92M$497.22M$492.48M$509.26M$488.31M
Total liabilities$946.34M$940.81M$595.27M$590.83M$572.42M$571.22M$575.47M$575.65M$568.68M$564.36M
Current liabilities$98.28M$91.92M$89.30M$79.72M$56.62M$55.60M$59.91M$60.05M$54.33M$50.22M
Total equity incl. NCI$518.05M$494.01M$473.10M$355.20M$318.10M$266.31M$228.60M$209.92M$189.89M$159.47M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$54.14M$49.89M$48.88M$44.51M$38.87M$43.38M$46.55M$52.15M$48.67M$48.54M
Accounts receivable$104.14M$90.73M$84.28M$80.70M$104.85M$142.03M$97.72M$90.13M$81.16M$81.94M
Goodwill$11.55M$11.55M$11.55M$11.55M$11.55M$11.55M$11.55M$11.55M$11.55M$11.99M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$12.91M$11.15M$10.35M$12.16M$9.54M$10.60M$10.29M$13.13M$13.03M$9.22M

Cash flow

TransMedics Group, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow$17.31M$24.53M$34.51M$69.57M$91.61M-$2.86M$19.66M$6.86M$25.72M-$3.44M
Capital expenditures$7.09M$36.66M$15.51M$7.62M$9.08M$27.04M$13.61M$48.20M$23.76M$44.17M
Investing cash flow-$7.09M-$36.66M-$15.51M-$7.62M-$9.08M-$27.04M-$13.61M-$47.76M-$23.76M-$44.17M
Financing cash flow$970.00K$3.76M$3.10M$3.64M$7.09M$3.03M$1.19M$7.86M$10.64M$3.18M
Net change in cash$10.94M-$8.69M$22.19M$65.60M$90.43M-$26.51M$6.56M-$32.66M$12.53M-$44.60M
Stock-based compensation$8.61M$9.95M$9.40M$9.14M$9.37M$8.96M$10.77M$7.94M$7.64M$6.87M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$10.24M$11.86M$7.47M$6.85M$6.73M$6.14M$5.68M$5.18M$4.60M$4.30M

Derived

TransMedics Group, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow$10.22M-$12.12M$19.00M$61.95M$82.53M-$29.89M$6.06M-$41.35M$1.96M-$47.61M
Gross margin59.6%58.2%58.1%58.8%61.4%61.5%59.2%55.9%60.6%61.9%
Operating margin12.5%7.6%13.2%16.2%23.2%19.1%7.1%3.6%10.9%12.8%
FCF margin5.4%-7.0%11.8%43.1%52.4%-20.8%5.0%-38.0%1.7%-49.2%
SBC / revenue4.5%5.7%5.8%6.4%6.0%6.2%8.9%7.3%6.7%7.1%
Current ratio6.62x6.74x7.14x7.69x9.86x9.10x8.30x8.20x9.37x9.72x
Revenue YoY growth20.7%21.2%32.2%32.2%37.7%48.2%49.8%63.7%117.9%133.1%
Net margin7.7%Unavailable65.6%16.9%22.2%Unavailable5.6%3.9%UnavailableUnavailable
R&D / revenue16.7%14.3%12.9%10.6%10.1%12.0%13.5%13.1%12.1%11.8%
CapEx / revenue3.7%21.1%9.7%5.3%5.8%18.8%11.2%44.3%20.8%45.6%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate24.3%13.8%-387.1%-5.6%3.5%3.7%1.9%0.7%-0.3%1.6%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TMDX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-10-29View SEC filing
10-Q · Filed 2025-07-30View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.